TISSUE REGENIX GROUP PLC — AGM Information 2020

Jun 30, 2020

National Storage Mechanism | Additional information

RNS Number : 5249R

Tissue Regenix Group PLC

30 June 2020

Tissue Regenix Group plc

Result of Annual General Meeting

Leeds, 30 June 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Group") the regenerative medical devices company, provides notification that, at the Group's AGM held earlier today, all resolutions were duly proposed to shareholders and passed.

The results of the poll are set out below:

Resolution	Type	Votes For	%	Votes Against	%	Votes Withheld
1	Ordinary	3,199,213,415	100.00	0.00	0.00	0.00
2	Ordinary	3,037,946,204	94.96	161,226,508	5.04	40,703
3	Ordinary	3,194,711,978	99.86	4,501,437	0.14	0.00
4	Ordinary	3,194,711,978	99.86	4,501,437	0.14	0.00
5	Ordinary	3,199,213,415	100.00	0.00	0.00	0.00
6	Ordinary	3,198,671,275	99.98	542,140	0.02	0.00
7	Ordinary	3,197,671,443	99.95	1,501,269	0.05	40,703
8	Special	3,195,822,395	99.94	1,850,317	0.06	1,540,703
9	Special	3,193,000,709	99.81	6,212,706	0.19	0.00

A "Vote withheld" is not counted in the calculation of the percentage of shares voted "For" or "Against" any resolution.

The full text of the resolutions passed at the AGM may be found in the Notice of AGM published on 5 June 2020.

For more Information:

Tissue Regenix Group plc Caitlin Pearson                                 Head of Communications	Tel: 0330 430 3073
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Jonathan Senior / Alex Price / Ben Maddison	Tel:  0207 710 7600
FTI Consulting  Simon Conway / Victoria Foster Mitchell / Mary Whittow	Tel: 0203 727 1000

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGSDESUSESSEDM